SDN 177
Latest Information Update: 27 Sep 2006
At a glance
- Originator Sindan
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malignant melanoma; Myeloid leukaemia
Most Recent Events
- 27 Sep 2006 Discontinued - Preclinical for Malignant melanoma in Romania (unspecified route)
- 27 Sep 2006 Discontinued - Preclinical for Myeloid leukaemia in Romania (unspecified route)
- 04 Dec 2000 Preclinical development for Malignant melanoma in Romania (Unknown route)